Lilly Trade Secrets Theft Case In China Puts Spotlight On Prevalent Problem
This article was originally published in The Pink Sheet Daily
Executive Summary
Two former Lilly biologists are indicted in the U.S. for passing early research in cancer, diabetes and metabolic disorders to Hengrui, a Chinese competitor. While few such cases become public, it is a constant worry for industry.
You may also be interested in...
Ex-Pfizer Employee Overseeing Xeljanz Global Marketing Sued For Trade Secret Theft
Pfizer says its former global marketing director emailed and copied hundreds of documents on product launch plans and steps to obtain government approvals before leaving the company in January.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.